Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy in High-Grade Soft Tissue Sarcoma
NCT00002641Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 1995
- Primary completion
- Feb 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of doxorubicin and ifosfamide in soft tissue sarcoma (STS) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall Survival. Started Feb 1995; status: completed.
02
Drugs
doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00002641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002641.